Roche abandons global diversity targets on concern over U.S. executive orders
Swiss drugmaker Roche has abandoned global targets for a more diverse workforce to avoid penalties from recent U.S. executive orders, the latest in a slew of companies to do so.
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for GLP-1 weight-loss drugs. Current runners-up Viking Therapeutics (VKTX 10.22%) and Roche Holdings (RHHBY 3.62%), up 11.3% and 4%, respectively, through 10:05 a.m.
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
Roche and Zealand Pharma inked a $5.3 billion deal Wednesday to collaborate on a weight-loss drug in the amylin class. The post Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion appeared first on Investor's Business Daily.
Roche And Zealand Team Up To Develop Petrelintide
Roche partnered with Zealand Pharma to co-develop and co-commercialize petrelintide, a novel amylin analog. Roche gains the most advanced amylin analog that is available and strengthens its obesity pipeline as petrelintide can be used as monotherapy and in combination with Roche's existing obesity candidates. Zealand Pharma gains substantial upfront cash, significant potential milestones, and a strong partner for global commercialization, and it also gets upside from petrelintide's use with Roche's candidates.
RHHBY Enters Into a $5.3B Deal With Zealand Pharma for Obesity Drug
Roche RHHBY announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma for an obesity candidate.
Roche and Zealand Pharma strike $5.3 billion deal for new obesity drug candidate
Swiss pharmaceutical giant Roche said Wednesday that it had struck a deal worth up to $5.3 billion to develop Danish biotech Zealand Pharma's obesity drug candidate. Shares of Zealand Pharma jumped as much as 29% shortly after the announcement, while Roche added 4.6%.
Roche takes big step in weight-loss field with $5.3 billion deal.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development deal.
Roche to develop, commercialize obesity drug with Zealand Pharma
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wednesday.
FDA Accepts RHHBY's sNDA for Gazyva in Treating Lupus Nephritis
Roche's filing is based on data from a late-stage study that shows a complete renal response benefit in lupus nephritis patients who received Gazyva.
Roche Gets FDA Approval for Acute Ischemic Stroke Drug for Adults
RHHBY's member company, Genentech, obtains FDA nod for TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the treatment of acute ischemic stroke in adults.
David Roche: ‘NATO is dead' and Europe defense spending needs to increase
Quantum Strategy's David Roche says Europe's defense spending needs to increase by at least $200 billion as he discusses the clash between U.S. President Donald Trump and Ukrainian President Volodymyr Zelenskyy.
David Roche: Germany's coalition government, a 'bumpy ride' going in the right direction
David Roche of Quantum Strategy discusses his optimism for the new German government following their recent elections. He believes the new government will be able enact reforms both domestically and on an EU level.
